When: Clean Q3 print with constructive lenacapavir commentary

Then: Full re-engagement

When: 5-7 sessions elapsed without breakout trigger activation

Then: Re-evaluate sidelined tranche

Measured defensive trim of 15 to 20 percent with hard stop at $141.50 on remaining position; re-engagement requires all three: RSI above 50, MACD histogram positive, and price reclaiming 10 EMA at $148

• 200 SMA sits at $135.36 versus current price $144.63, providing $9.27 buffer (not 'nearly seven dollars' as aggressive claims), nearly three full ATR moves of downside
• RSI at 44 is neutral, not capitulation; MACD histogram at minus 1.03 is early-stage bearish momentum, not extended selling pressure
• Q1 2026 normalized operating income of $2.54 billion, EBITDA run rate near $15 billion, trailing twelve-month FCF of $9.77 billion
• Q2 $11.2 billion acquisition closed on schedule; Net Debt to EBITDA at 1.6x is investment-grade comfortable
• $10.5 billion net loss was non-cash IPR&D write-offs from purchase accounting, not operational deterioration; Q1 2026 operating cash flow was $3.57 billion
• Proposed stop at $148 is only 2.3% from entry at $144.63, within normal daily ATR noise of $3.36; disciplined stop should be below 50 SMA at $142.95 with buffer to lower Bollinger band at $141.97
• Macro environment favors defensives: 10-year Treasury at multi-decade highs, hawkish Fed, 8% recession odds on Polymarket, consumer discretionary being pummeled
• GILD defensive profile: 2.27% yield, 14.6x forward P/E, 0.33 beta, the textbook defensive anchor for this rate regime
• September peak was $154.20; current $144.63 represents a routine 5% pullback within structurally intact long-term uptrend
• Re-engagement criteria require ALL THREE: RSI crosses above 50, MACD histogram turns positive, and price reclaims 10 EMA at $148

→ vs aggressive: Wrong on 200 SMA buffer: actual buffer is $9.27 (not 'nearly seven dollars'), nearly three ATR moves of downside not two; mischaracterizes Q2 acquisition as 'financial leverage' when it was strategic and on schedule with 1.6x Net Debt/EBITDA; stop loss at $148 is within daily noise and will constantly trigger on routine volatility in a beta-0.33 stock

→ vs neutral: Too passive; needs a defined action plan beyond 'just hold' with vague reference to $142.95; requires specific trim percentage, hard stop level, and explicit re-engagement criteria rather than passive monitoring

20-25% position trim; replace $148 stop loss with 50 SMA ($142.95) as reassessment trigger; re-engage when price reclaims 10 EMA ($148) plus any two of: RSI above 50, MACD histogram positive, or positive catalyst

• Volume: 5.68 million shares (below normal)
• VWMA: flat around $148-$150
• Net Debt to EBITDA: 1.6x post-deal
• Operating cash flow Q1 2026: $3.57 billion
• Trailing free cash flow: $9.77 billion
• Beta: 0.33
• ATR: $3.36
• RSI: collapsed from 66 to 44
• MACD: crossed bearish
• Price relative to 10 EMA: $3.37 below
• 200 SMA: $135.36
• 50 SMA: $142.95 (buffer of $1.68 against ATR)
• 10 EMA: $148
• 200 SMA cushion: $9.27
• Re-engagement criteria: price reclaiming 10 EMA ($148) plus at least two of: RSI above 50, MACD histogram positive, or positive earnings/catalyst event
• Macro context: 10-year at multi-decade highs, mortgage rates at 7.58%, 8% recession odds pointing toward defensive rotation

→ vs aggressive: Bear narrative on 'coordinated technical breakdown' lacks volume confirmation; volume of 5.68 million shares is below normal, not confirming distribution; VWMA is flat at $148-$150, not rolling over

→ vs aggressive: Q2 acquisition cited as financial stress is unsupported; Net Debt to EBITDA at 1.6x post-deal with investment-grade rating and $3.57B Q1 2026 operating cash flow shows no liquidity pressure

→ vs conservative: Defensive-pharma narrative causes dismissal of real technical deterioration; MACD did cross bearish, RSI did collapse to 44, price is $3.37 below 10 EMA - these signals warrant some action

→ vs conservative: 50 SMA at $142.95 has buffer of only $1.68 against ATR of $3.36, leaving minimal cushion in a beta-0.33 name

→ vs conservative: Triple-confirmation re-engagement criteria (RSI above 50, MACD histogram positive, price reclaiming 10 EMA simultaneously) is too restrictive and will result in buying back at $150-$152 after missing the $142-$144 entry zone